Filing Flows › Insmed (INSM) › Q2 2026
Insmed (INSM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Insmed (INSM) reported revenue of $425M for the second quarter 2026 (Q2 2026), +296% from a year earlier and +39% from the quarter before. Operating margin was -0.4%, net loss $13.2M (3.1% of revenue).
Insmed, Q2 2026: revenue $425M (+296% year over year), operating margin -0.4%, net loss $13.2M, operating cash flow −$88.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $425M | +39% | +296% |
| Operating profit | −$1.5M | — | — |
| Net earnings | −$13.2M | — | — |
| Operating cash flow | −$88.8M | — | — |
What changed
Revenue was $425.5M in Q2 2026, up 296% year over year and up 39% from the previous quarter. BRINSUPRI was the largest line at 73% of revenue. ARIKAYCE added $8.9M year over year (up 8%), 3% of the total change.
Operating costs exceeded revenue by $1.5M, an operating margin of -0.4%. Total costs grew 2% against revenue growth of 296%. The quarter ended with a net loss of $13.2M, narrower than the previous quarter's $163.6M loss. Net interest and other expense of $9.8M was the main reason.
Operating cash flow was −$88.8M. Non-cash charges added back $5.3M of depreciation and amortization and $41.3M of share-based compensation. Working capital and other items used $122.1M. Capital expenditures of $6.3M exceeded it, leaving free cash flow of −$95.1M.
Questions
What was Insmed's revenue in the second quarter 2026?
Insmed (INSM) reported revenue of $425M for the second quarter 2026 (Q2 2026), +296% from a year earlier and +39% from the quarter before.
Was Insmed profitable in the second quarter 2026?
Operating loss was $1.5M (-0.4% of revenue) and net loss $13.2M.
Source: Insmed 10-Q on SEC EDGAR.